Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03898180
Other study ID # 7902-011
Secondary ID MK-7902-011E7080
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date May 6, 2019
Est. completion date July 1, 2024

Study information

Verified date January 2024
Source Merck Sharp & Dohme LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in the treatment of cisplatin-ineligible participants with a Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, or in participants ineligible for any platinum-containing chemotherapy regardless of CPS, with advanced/unresectable or metastatic urothelial carcinoma (UC). The primary hypotheses for this study are that: 1. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR), and 2. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Overall Survival (OS). With Amendment 3 (effective: September [Sep]-24-2021) participants discontinued lenvatinib and placebo; participants who remained on treatment in the study arms received open-label pembrolizumab. With Amendment 3 the external Data Monitoring Committee was discontinued. With Amendment 4 (effective: December-5-2022) Second Course will no longer be offered. Any participant receiving Second Course treatment prior to initiation of Amendment 4 will be able to complete treatment as planned. With Amendment 4 study participation will end after the final administration of pembrolizumab. Participants who either complete 35 administrations of pembrolizumab or discontinue pembrolizumab will discontinue from the study following the safety follow-up visit. AEs and spontaneously reported pregnancies will be reported and followed per protocol. All participants in efficacy follow-up prior to initiation of Amendment 4 will stop efficacy assessments and be discontinued from the study. All participants in survival follow-up prior to initiation of Amendment 4 are considered to have completed the study and should have a final survival contact. The overall study ends when the last participant completes the last study-related contact or visit, withdraws from the study, or is lost to follow-up.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 487
Est. completion date July 1, 2024
Est. primary completion date July 26, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Has a histologically or cytologically confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial carcinoma (UC) of the renal pelvis, ureter (upper urinary tract), bladder, or urethra. - Has =1 measurable target lesion per RECIST 1.1 as assessed by the local site investigator/radiologist. - Has provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated and adequate for Programmed Death-Ligand 1 (PD-L1) evaluation. - Has received no prior systemic chemotherapy for advanced or metastatic UC with the following exceptions: - Neoadjuvant (prior to surgery) platinum-based chemotherapy for treatment of muscle-invasive bladder cancer with recurrence >12 months from completion of the therapy is permitted. - Adjuvant (following surgery) platinum-based chemotherapy following radical cystectomy, with recurrence >12 months from completion of the therapy, is permitted. - Meets criteria for either option a or option b (below): - a. Has a tumor(s) with PD-L1 combined positive score (CPS) =10 and is considered ineligible to receive cisplatin-based combination therapy, based on 1 of the following: - Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 2 within 7 days prior to randomization - National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Grade =2 audiometric hearing loss - NCI CTCAE Version 4.0 Grade =2 peripheral neuropathy OR - b. In the opinion of the investigator, is considered ineligible to receive any platinum-based chemotherapy (i.e., ineligible for cisplatin and carboplatin) based on: - ECOG PS of 2 within 7 days prior to randomization and =1 of the following: - Documented visceral metastatic disease - NCI CTCAE Version 4.0 Grade =2 audiometric hearing loss - NCI CTCAE Version 4.0 Grade =2 peripheral neuropathy - Other reason for the participant's being unable to receive both cisplatin and carboplatin safely. Additional criteria for platinum ineligibility will be considered and allowed on a case-by-case basis, following consultation with the Sponsor. Note: Participants considered ineligible for any platinum-based chemotherapy are eligible for this study regardless of their tumor PD-L1 status. - Has ECOG PS 0, 1, or 2 within 7 days prior to randomization and a life expectancy of =3 months. - Male participants are eligible to participate if they agree to the following during the treatment period and for =30 days after the last dose of pembrolizumab or lenvatinib/placebo: - Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR - Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause as detailed below: - Agrees to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration. - A female participant is eligible to participate if she is not pregnant or breastfeeding and if she is not a WOCBP OR is a WOCBP and is using a contraceptive method that is highly effective (with a failure rate of <1% per year) with low user dependency, or is abstinent from heterosexual intercourse as her preferred and usual lifestyle during the intervention period and for =120 days post pembrolizumab or =30 days post lenvatinib/placebo. - Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP =150/90 mm Hg at screening and no change in antihypertensive medications within 1 week prior to randomization. - Has adequate organ function. Exclusion Criteria: - Has disease that is suitable for local therapy administered with curative intent (e.g. chemotherapy and radiation for Stage 3 disease). - Has tumor with any neuroendocrine or small cell component. - Has a history of a gastrointestinal condition or procedure (e.g. gastric bypass, malabsorption) that, in the opinion of the investigator, may affect oral drug absorption. - Has had major surgery within 3 weeks prior to the first dose of study treatment - Has a pre-existing Grade =3 gastrointestinal or non-gastrointestinal fistula. - Has radiographic evidence of major blood vessel invasion/infiltration, or has had clinically significant hemoptysis (=0.5 teaspoon of bright red blood) or tumor bleeding within 2 weeks prior to the first dose of study treatment. - Has had significant cardiovascular impairment within 12 months of the first dose of study treatment, such as history of New York Heart Association (NYHA) >Class II congestive heart failure, unstable angina, myocardial infarction or cerebrovascular accident (CVA)/stroke, cardiac revascularization procedure, or cardiac arrhythmia associated with hemodynamic instability. - Has known intolerance or severe hypersensitivity (Grade =3) to pembrolizumab or lenvatinib or any of their excipients - Has received lenvatinib as monotherapy or in combination with a programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitor or has previously been enrolled in a clinical study evaluating lenvatinib for bladder cancer, regardless of the treatment received. - Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 inhibitor, indoleamine-pyrrole 2,3 dioxygenase (IDO1) inhibitor, or agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4], OX 40, CD137), or any other antibody or drug targeting T-cell costimulatory pathways in the adjuvant or advanced/metastatic setting. - Has received prior radiotherapy to a metastatic site without the use of chemotherapy radiosensitization within 3 weeks of the first dose of study treatment, with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks before the start of study treatment. Participants must have recovered from all radiation-related toxicities, and must not require corticosteroids. - Has received a live vaccine within 30 days prior to the first dose of study treatment. - In the investigator's judgment, has not recovered from toxicity or other complications from any major surgery prior to starting study treatment. - Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent. - Has history or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful. - Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a dose exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization. - Has had an active malignancy (except locally advanced or metastatic UC) within the past 36 months. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) who have undergone potentially curative therapy are not excluded. - Has a history of prostate cancer (T2NXMX or lower with Gleason score =7) treated with definitive intent (surgically or with radiation therapy) =1 year prior to study entry is acceptable, provided that the participant is considered prostate cancer-free. - Has central nervous system (CNS) metastases, unless the participant has completed local therapy (e.g. whole brain radiation therapy, surgery, or radiosurgery) and has discontinued use of corticosteroids for this indication for =4 weeks before starting study treatment. Any signs (e.g. radiologic) or symptoms of CNS metastases must be stable for =4 weeks before starting study treatment. - Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e, with disease-modifying agents, corticosteroids, or immunosuppressive drugs). - Has a history of (non-infectious) pneumonitis that required systemic steroids, or current pneumonitis. - Has an active infection requiring systemic therapy. - Has a known history of human immunodeficiency virus (HIV) infection. - Has a known history of or is positive for active hepatitis B virus (HBV) or has active hepatitis C virus (HCV). - Has active tuberculosis (TB). - Is receiving hemodialysis. - Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab and lenvatinib/placebo. - Has had an allogeneic tissue/solid organ transplant.

Study Design


Intervention

Biological:
Pembrolizumab
IV infusion
Drug:
Lenvatinib
oral capsule
Placebo for lenvatinib
oral capsule

Locations

Country Name City State
Argentina Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0577) Berazategui Buenos Aires
Argentina Centro de Urología CDU ( Site 0590) Buenos Aires Caba
Argentina Centro Medico Dra De Salvo ( Site 0593) Buenos Aires
Argentina Instituto de Investigaciones Metabolicas ( Site 0589) Buenos Aires
Argentina Instituto Medico Alexander Fleming ( Site 0578) Buenos Aires Caba
Argentina CEMAIC ( Site 0581) Cordoba
Argentina Centro Oncologico de Integracion Regional. COIR ( Site 0576) Mendoza
Argentina Centro Oncológico de Rosario ( Site 0584) Rosario Santa Fe
Argentina Centro de Investigaciones Clinicas - Clinica Viedma ( Site 0585) Viedma Rio Negro
Australia Monash Health ( Site 0160) Clayton Victoria
Australia Peninsula Health Frankston Hospital ( Site 0153) Frankston Victoria
Australia Austin Health-Austin Hospital ( Site 0154) Heidelberg Victoria
Australia Macquarie University ( Site 0151) North Ryde New South Wales
Australia Mater Misericordiae Ltd ( Site 0158) South Brisbane Queensland
Canada Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0101) Hamilton Ontario
Canada Lakeridge Health ( Site 0103) Oshawa Ontario
Canada CHUQ-Univ Laval-Hotel Dieu de Quebec ( Site 0104) Quebec
Canada CIUSSS de l Estrie Centre Hospitalier Universitaire de Sherbrooke ( Site 0102) Sherbrooke Quebec
Canada Sunnybrook Research Institute ( Site 0106) Toronto Ontario
China Fifth Medical Center of CPLA General Hospital ( Site 0732) Beijing Beijing
China Peking University First Hospital ( Site 0726) Beijing Beijing
China Peking University Third Hospital ( Site 0727) Beijing Beijing
China Hunan Cancer Hospital ( Site 0745) Changsha Hunan
China Chongqing Cancer Hospital ( Site 0741) Chongging Chongqing
China Sun Yat-Sen University Cancer Center ( Site 0752) Guangdong Guangdong
China Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ( Site 0746) Guangzhou Guangdong
China The First Affiliated Hospital of Guangzhou Medical University ( Site 0749) Guangzhou Guangdong
China Second Affiliated Hospital, Zhejiang University ( Site 0734) Hangzhou Zhejiang
China Zhejiang Provincial People's Hospital ( Site 0735) Hangzhou Zhejiang
China Harbin Medical University Cancer Hospital ( Site 0750) Harbin Heilongjiang
China Nanjing Drum Tower Hospital ( Site 0737) Nanjing Jiangsu
China Fudan University Shanghai Cancer Center ( Site 0721) Shanghai Shanghai
China Zhongshan Hospital Fudan University ( Site 0725) Shanghai Shanghai
China Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0751) Urumqi Xinjiang
China Hubei Cancer Hospital ( Site 0744) Wuhan Hubei
China The First Affiliated Hospital of Xiamen University ( Site 0743) Xiamen Fujian
China The First Affiliated Hospital of Xi an Jiaotong University ( Site 0738) Xian Shanxi
Denmark Aalborg Universitets Hospital ( Site 0684) Aalborg Nordjylland
Denmark Aarhus Universitets hospital ( Site 0683) Aarhus N Midtjylland
Denmark Rigshospitalet ( Site 0680) Copenhagen Hovedstaden
Denmark Herlev Hospital ( Site 0681) Herlev Hovedstaden
Denmark Odense Universitetshospital ( Site 0682) Odense Syddanmark
France Institut de Cancerologie de l Ouest Site Paul Papin ( Site 0236) Angers Maine-et-Loire
France Centre Hospitalier de la Cote Basque ( Site 0239) Bayonne Pyrenees-Atlantiques
France CHU de Bordeaux- Hopital Saint Andre ( Site 0235) Bordeaux Gironde
France CHD Vendee-onco-hematologie ( Site 0251) La Roche sur Yon Vendee
France Centre Leon Berard ( Site 0244) Lyon Rhone
France Hopital de la Timone ( Site 0246) Marseille Bouches-du-Rhone
France Centre de Cancerologie du Grand Montpellier ( Site 0249) Montpellier Languedoc-Roussillon
France Centre D Oncologie de Gentilly ( Site 0240) Nancy Meurthe-et-Moselle
France Institut Curie ( Site 0237) Paris
France CHU Poitiers ( Site 0253) Poitiers Ain
France CHIC Quimper ( Site 0245) Quimper Finistere
France Centre Rene Gauducheau ICO ( Site 0250) Saint Herblain Loire-Atlantique
France Institut de Cancerologie Strasbourg Europe ( Site 0232) Strasbourg Alsace
France Clinique Pasteur ( Site 0252) Tolouse Haute-Garonne
France Institut Gustave Roussy ( Site 0243) Villejuif Val-de-Marne
Germany Universitaetsklinikum Essen ( Site 0274) Essen Nordrhein-Westfalen
Germany Universitaetsmedizin Goettingen ( Site 0281) Gottingen Niedersachsen
Germany Universitaetsklinikum Hamburg-Eppendorf ( Site 0282) Hamburg
Germany Staedtisches Krankenhaus Kiel GmbH ( Site 0285) Kiel Schleswig-Holstein
Germany Universitaetsklinikum Schleswig-Holstein-Campus Lubeck ( Site 0277) Luebeck Schleswig-Holstein
Germany Universitaetsklinikum Giessen und Marburg GmbH ( Site 0284) Marburg Hessen
Germany Helios Kliniken Schwerin GmbH ( Site 0278) Schwerin Mecklenburg-Vorpommern
Germany Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0271) Tuebingen Baden-Wurttemberg
Hungary Bajcsy Zsilinszki Korhaz es Rendelointezet ( Site 0509) Budapest
Hungary Orszagos Onkologiai Intezet ( Site 0503) Budapest
Hungary Uzsoki Utcai Korhaz ( Site 0508) Budapest
Hungary Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 0504) Kaposvar
Hungary Bacs-Kiskun Megyei Korhaz ( Site 0510) Kecskemet Bacs-Kiskun
Hungary Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás Ce Miskolc Borsod-Abauj-Zemplen
Hungary Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0507) Szolnok Jasz-Nagykun-Szolnok
Hungary Markusovszky Egyetemi Oktatokorhaz ( Site 0502) Szombathely Vas
Israel Ha Emek Medical Center ( Site 0560) Afula
Israel Assuta Ashdod Public ( Site 0562) Ashdod
Israel Rambam Medical Center ( Site 0552) Haifa
Israel Hadassah Ein Kerem Medical Center ( Site 0558) Jerusalem
Israel Shaare Zedek Medical Center ( Site 0559) Jerusalem
Israel Meir Medical Center ( Site 0554) Kfar Saba
Israel Rabin Medical Center ( Site 0553) Petach-Tikwa
Israel Sheba Medical Center ( Site 0551) Ramat Gan
Israel Sourasky Medical Center ( Site 0561) Tel Aviv
Israel Assaf Harofeh Medical Center ( Site 0556) Zerifin
Italy Centro di Riferimento Oncologico CRO ( Site 0304) Aviano Pordenone
Italy Istituto Tumori Giovanni Paolo II ( Site 0306) Bari
Italy Policlinico S. Orsola - Malpighi (Bologna) ( Site 0302) Bologna
Italy Azienda Ospedaliera per l Emergenza Cannizzaro ( Site 0305) Catania
Italy ASST Grande Ospedale Metropolitano Niguarda ( Site 0307) Milano Lombardia
Italy Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0301) Milano
Italy Ospedale San Raffaele-Oncologia Medica ( Site 0309) Milano Lombardia
Italy Azienda Ospedaliera Santa Maria ( Site 0303) Terni
Italy Ospedale Borgo Roma-Oncologia ( Site 0308) Verona
Japan Akita University Hospital ( Site 0124) Akita
Japan Chiba Cancer Center ( Site 0127) Chiba
Japan Saitama Medical University International Medical Center ( Site 0125) Hidaka Saitama
Japan Hirosaki University Hospital ( Site 0123) Hirosaki Aomori
Japan Nara Medical University Hospital ( Site 0133) Kashihara Nara
Japan National Cancer Center Hospital East ( Site 0128) Kashiwa Chiba
Japan Nagasaki University Hospital ( Site 0136) Nagasaki
Japan Osaka City University Hospital ( Site 0132) Osaka
Japan Kitasato University Hospital ( Site 0129) Sagamihara Kanagawa
Japan Sapporo Medical University Hospital ( Site 0122) Sapporo Hokkaido
Japan Tokushima University Hospital ( Site 0134) Tokushima
Japan Medical Hospital, Tokyo Medical And Dental University ( Site 0130) Tokyo
Japan Ehime University Hospital ( Site 0137) Toon Ehime
Japan University of Tsukuba Hospital ( Site 0126) Tsukuba Ibaraki
Japan Yamaguchi University Hospital ( Site 0135) Ube Yamaguchi
Korea, Republic of Chungnam National University Hospital ( Site 0195) Daejeon Taejon-Kwangyokshi
Korea, Republic of National Cancer Center ( Site 0196) Goyang-si Kyonggi-do
Korea, Republic of Chonnam National University Hwasun Hospital ( Site 0194) Hwasun Gun Jeonranamdo
Korea, Republic of Korea University Anam Hospital ( Site 0197) Seoul
Korea, Republic of Samsung Medical Center ( Site 0193) Seoul
Korea, Republic of Seoul National University Hospital ( Site 0191) Seoul
Korea, Republic of Severance Hospital ( Site 0192) Seoul
Korea, Republic of Veterans Health Service Medical Center ( Site 0198) Seoul
Netherlands Ziekenhuis Rijnstate ( Site 0342) Arnhem Gelderland
Netherlands Amphia Ziekenhuis Breda ( Site 0331) Breda Noord-Brabant
Netherlands Haga Ziekenhuis ( Site 0333) Den Haag Zuid-Holland
Netherlands Deventer Ziekenhuis ( Site 0341) Deventer Overijssel
Netherlands Maastricht Universitair Medisch Centrum - MUMC ( Site 0334) Maastricht Limburg
Netherlands Erasmus MC ( Site 0332) Rotterdam Zuid-Holland
Netherlands St. Antonius Ziekenhuis ( Site 0335) Utrecht
Netherlands VieCuri Medisch Centrum ( Site 0340) Venlo Limburg
Poland Szpital Miejski im. Jana Pawla II w Bielsku-Bialej ( Site 0542) Bielsko-Biala Slaskie
Poland Europejskie Centrum Zdrowia Otwock ( Site 0532) Otwock Mazowieckie
Poland Urologica Praktyka Lekarska Adam Marcheluk ( Site 0543) Siedlce Mazowieckie
Poland Szpital Wojewodzki ( Site 1062) Tarnow Malopolskie
Poland Luxmed Onkologia sp. z o. o. ( Site 0541) Warszawa Mazowieckie
Poland Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 0535) Wroclaw Dolnoslaskie
Russian Federation GBUZ Leningrad Regional Clinical Oncology Dispensary ( Site 0426) Kuzmolovskiy Settlement Leningradskaya Oblast
Russian Federation Central Clinical Hospital with Polyclinic ( Site 0415) Moscow Moskva
Russian Federation Medical Rehabilitation Center ( Site 0411) Moscow Moskva
Russian Federation Russian Scientific Center of Roentgenoradiology ( Site 0424) Moscow Moskva
Russian Federation Murmansk Regional Oncology Dispensary ( Site 0420) Murmansk Murmanskaya Oblast
Russian Federation Volga District Medical Center Federal Medical and Biological Agency ( Site 0413) Nizhny Novgorod Nizhegorodskaya Oblast
Russian Federation Omsk Clinical Oncology Dispensary ( Site 0418) Omsk Omskaya Oblast
Russian Federation Clinical Hospital Saint Luka ( Site 0421) Saint-Petersburg Sankt-Peterburg
Russian Federation Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 0414) Yaroslavl Yaroslavskaya Oblast
Spain Hospital Teresa Herrera - Chuac ( Site 0357) A Coruna La Coruna
Spain Hospital Infanta Cristina ( Site 0355) Badajoz
Spain Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 0351) Badalona Barcelona
Spain Hospital General Universitari Vall d Hebron ( Site 0358) Barcelona
Spain ICO L Hospitalet ( Site 0361) Hospitalet de Llobregat Barcelona
Spain Hospital La Princesa ( Site 0862) Madrid
Spain Hospital Universitario Gregorio Maranon ( Site 0352) Madrid
Spain Hospital Universitario HM Sanchinarro ( Site 0356) Madrid Madrid, Comunidad De
Spain Xarxa Assistencial Universitaria Manresa ( Site 0354) Manresa Barcelona
Taiwan Kaohsiung Chang Gung Memorial Hospital ( Site 0217) Kaohsiung
Taiwan Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 0216) Kaoshiung Kaohsiung
Taiwan China Medical University Hospital ( Site 0213) Taichung
Taiwan Taichung Veterans General Hospital ( Site 0214) Taichung
Taiwan National Cheng Kung University Hospital ( Site 0215) Tainan
Taiwan National Taiwan University Hospital ( Site 0211) Taipei
Taiwan Taipei Veterans General Hospital ( Site 0212) Taipei
Turkey Cukurova Universitesi Tip Fakultesi Balcali Hastanesi ( Site 0457) Adana
Turkey Ankara Sehir Hastanesi ( Site 0455) Ankara
Turkey Antalya Memorial Hospital Department of Medical Oncology ( Site 0461) Antalya
Turkey Göztepe Prof. Dr. Süleyman Yalçin Sehir Hastanesi-oncology ( Site 0459) Istanbul
Turkey Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0454) Istanbul
Turkey Ege Universitesi Tulay Aktas Onkoloji Hastanesi ( Site 0462) Izmir
Turkey Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0456) Konya
Turkey Sakarya Universitesi Tip Fakultesi Arastirma Hastanesi ( Site 0460) Sakarya
United Kingdom Kent and Canterbury Hospital ( Site 0390) Canterbury Kent
United Kingdom Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 0378) London London, City Of
United Kingdom Saint Bartholomew s Hospital - London ( Site 0386) London London, City Of
United Kingdom University College London Hospital NHS Foundation Trust ( Site 0380) London London, City Of
United Kingdom Nottingham University Hospital NHS Trust ( Site 0383) Nottingham
United Kingdom Derriford Hospital ( Site 0388) Plymouth
United Kingdom Royal Preston Hospital ( Site 0379) Preston Lancashire
United Kingdom Queens Hospital-Purple Zone ( Site 0377) Romford Essex
United Kingdom Weston Park Hospital ( Site 0387) Sheffield Derbyshire
United Kingdom Lister Hospital ( Site 0376) Stevenage Hertfordshire
United Kingdom Royal Stoke University Hospital Univ. Hosps of North Midlands NHST ( Site 0392) Stoke-on-Trent
United States St. Peter's Hospital Cancer Care Center ( Site 0042) Albany New York
United States Medical University of South Carolina-Hollings Cancer Center ( Site 0029) Charleston South Carolina
United States University of Chicago ( Site 0039) Chicago Illinois
United States Community Cancer Institute ( Site 0777) Clovis California
United States Karmanos Cancer Institute ( Site 0712) Detroit Michigan
United States Banner MD Anderson Cancer Center ( Site 0016) Gilbert Arizona
United States Joliet Oncology Hematology ( Site 0091) Joliet Illinois
United States Comprehensive Cancer Centers of Nevada ( Site 0005) Las Vegas Nevada
United States Northwest Georgia Oncology Centers PC ( Site 0707) Marietta Georgia
United States Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0002) New York New York
United States University of California Irvine Medical Center ( Site 0078) Orange California
United States Thomas Jefferson University Hospital ( Site 0051) Philadelphia Pennsylvania
United States Quincy Medical Group ( Site 0022) Quincy Illinois
United States Virginia Cancer Institute ( Site 0099) Richmond Virginia
United States Mercy Hospital Saint Louis - David C. Pratt Cancer Center ( Site 0095) Saint Louis Missouri
United States John Wayne Cancer Institute ( Site 0017) Santa Monica California
United States New England Cancer Specialists ( Site 0047) Scarborough Maine
United States Seattle Cancer Care Alliance ( Site 0003) Seattle Washington
United States Cancer Care Northwest ( Site 0009) Spokane Washington
United States Baylor Scott & White Medical Center - Temple ( Site 0706) Temple Texas
United States Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0774) Tulsa Oklahoma

Sponsors (2)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC Eisai Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Canada,  China,  Denmark,  France,  Germany,  Hungary,  Israel,  Italy,  Japan,  Korea, Republic of,  Netherlands,  Poland,  Russian Federation,  Spain,  Taiwan,  Turkey,  United Kingdom, 

References & Publications (1)

Matsubara N, de Wit R, Balar AV, Siefker-Radtke AO, Zolnierek J, Csoszi T, Shin SJ, Park SH, Atduev V, Gumus M, Su YL, Karaca SB, Cutuli HJ, Sendur MAN, Shen L, O'Hara K, Okpara CE, Franco S, Moreno BH, Grivas P, Loriot Y. Pembrolizumab with or Without Le — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free Survival (PFS) PFS was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR), or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of =5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by BICR per RECIST 1.1 is presented. Protocol-specified final analysis for this primary outcome measure was performed with an analysis data cut-off date of July-26-2021. Up to ~25 months
Primary Overall Survival (OS) OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. Protocol-specified final analysis for this primary outcome measure was performed with an analysis data cut-off date of July-26-2021. Up to ~25 months
Secondary Objective Response Rate (ORR) ORR was defined as the percentage of participants who had a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR. The percentage of participants who experienced a CR or PR is presented. Protocol-specified final analysis for this secondary outcome measure was performed with an analysis data cut-off date of July-26-2021. Up to ~25 months
Secondary Duration of Response (DOR) For participants who demonstrated a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as =20% increase in the sum of diameters of target lesions as well as an absolute increase of =5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. The DOR as assessed by BICR per RECIST 1.1 for participants who experienced a confirmed CR or PR is presented. Protocol-specified final analysis for this secondary outcome measure was performed with an analysis data cut-off date of July-26-2021. Up to ~25 months
Secondary Disease Control Rate (DCR) DCR was defined at the percentage of participants who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: =20% increase in the sum of diameters of target lesions and an absolute increase of =5 mm. The appearance of one or more new lesions was also considered PD]. DCR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. The DCR as assessed by BICR per RECIST 1.1 is presented. Protocol-specified final analysis for this secondary outcome measure was performed with an analysis data cut-off date of July-26-2021. Up to ~25 months
Secondary Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and Quality of Life (QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score will be presented. A higher score indicates a better outcome. Baseline and Up to ~60 months
Secondary Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and Quality of Life (QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). TTD is defined as the time from baseline to the first onset of a =10-point negative change (decrease) from baseline in GHS (EORTC QLQ-C30 Item 29) & QoL (EORTC QLQ-C30 Item 30) combined score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a =10-point negative change (decrease) from baseline in GHS and QoL combined score, will be presented. A longer TTD indicates a better outcome. Up to ~60 months
Secondary Number of Participants Who Experience an Adverse Event (AE) An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is presented. Protocol-specified final analysis for this secondary outcome measure was performed with an analysis data cut-off date of July-26-2021. Up to ~25 months
Secondary Number of Participants Who Discontinue Study Treatment Due to an AE An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented. Protocol-specified final analysis for this secondary outcome measure was performed with an analysis data cut-off date of July-26-2021. Up to ~25 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT05775874 - A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC Phase 2
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Recruiting NCT04617756 - Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract Phase 2
Recruiting NCT06116396 - Liquid Biospy for Urinary Cancers
Recruiting NCT05723991 - Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma Phase 4
Active, not recruiting NCT03039413 - Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy Early Phase 1
Completed NCT02795156 - Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Phase 2
Terminated NCT03915405 - KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Completed NCT04452214 - A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT05911295 - Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Phase 3
Terminated NCT01093066 - Prospective Multicentric Evaluation of a Bladder Preservation Strategy Phase 2
Terminated NCT01042795 - Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy Phase 2
Recruiting NCT06022757 - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) Phase 1/Phase 2
Recruiting NCT03212404 - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Phase 1
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2